Nutrient- and non-nutrient-based natural health product (NHP) use in adults with mood disorders: Prevalence, characteristics and potential for exposure to adverse events

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Davison, Karen M ^a,b   Kaplan, Bonnie J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adverse events; Mood disorders; Natural health products

Indexed keywords

ANTIDEPRESSANT AGENT; BIOTIN; MAGNESIUM; MINERAL; MOOD STABILIZER; NATURAL PRODUCT; NEUROLEPTIC AGENT; NICOTINIC ACID; PANTETHINE; PANTOTHENIC ACID; POTASSIUM; VITAMIN B COMPLEX;

ABDOMINAL DISCOMFORT; ADULT; ADVERSE OUTCOME; ARTICLE; DATA BASE; DIARRHEA; FEMALE; FOOD; FOOD INTAKE; HEALTH CARE PERSONNEL; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MOOD DISORDER; NAUSEA; NUTRIENT; PERICARDIAL EFFUSION; PLEURA EFFUSION; POPULATION; PREVALENCE; VOMITING;

AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NUTRITION SURVEYS;

EID: 84875883437     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-80     Document Type: Article

References (106)

1. Health Canada Natural Health Products 2012, Ottawa: Health Canada, Retrieved: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index-eng.php, Health Canada.
2. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results from a follow up national survey. JAMA 1998, 280:1569-1575. 10.1001/jama.280.18.1569, 9820257.
3. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001, 9:2-11. 10.1054/ctim.2000.0407, 11264963.
4. Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ 2000, 78:252-257. 2560678, 10743298.
5. Simpson JE. Utilization patterns and trends. Health Policy Research Bulletin 2003, 7:9-13.
6. Wahlström M, Sihvo S, Haukkala A, Kiviruusu O, Pirkola S, Isometsä E. Use of mental health services and complementary and alternative medicine in persons with common mental disorders. Acta Psychiatr Scand 2008, 118:73-80. 10.1111/j.1600-0447.2008.01192.x, 18595177.
7. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics 2004, Hyattsville, Maryland: National Center for Health Statistics.
8. Unützer J, Klap R, Sturm R, Young AS, Marmon T, Shatkin J, Wells KB. Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 2000, 157:1851-1857. 10.1176/appi.ajp.157.11.1851, 11058485.
9. Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, Eisenberg DM. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001, 158:289-294. 10.1176/appi.ajp.158.2.289, 11156813.
10. Wang J, Patten S, Russell M. Alternative medicine use by individuals with major depression. Can J Psychiatry 2001, 46:528-533.
11. Assion HJ, Zarouchas I, Multamäki S, Zolotova J, Schröder SG. Patients' use of alternative methods parallel to psychiatric therapy: does the migrational background matter. Acta Psychiatr Scand 2007, 116:220-225. 10.1111/j.1600-0447.2007.01010.x, 17655564.
12. Martin TG. Serotonin syndrome. Ann Emerg Med 1996, 28:520-526. 10.1016/S0196-0644(96)70116-6, 8909274.
13. World Alliance for Patient Safety WHO Draft Guidelines for Adverse Event Reporting and Learning Systems from Information to Action 2005, Geneva: WHO, World Alliance for Patient Safety.
14. Bell I, Edman J, Morrow F, Marby DW, Perrone G, Kayne HL, Greenwald M, Cole JO. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr 1992, 11:159-163.
15. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2010, 44:32-41. 10.1016/j.jpsychires.2009.06.003, 19616220.
16. Kaplan BJ, Simpson JSA, Ferre RC, Gorman CP, McMullen DM, Crawford SG. Effective mood stabilization in bipolar disorders with a chelated mineral supplement. J Clin Psychiatry 2001, 62:936-944. 10.4088/JCP.v62n1204, 11780873.
17. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord 2011, 13:454-465. 10.1111/j.1399-5618.2011.00945.x, 22017215.
18. Rosner B. Fundamentals of Biostatistics 2004, Pacific Grove: Duxbury.
19. Barr SI. British Columbia Nutrition Survey: Report on Supplements 2004, Victoria, BC: BC Ministry of Health Services.
20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP) 2001, New York: Biometrics Research, New York State Psychiatric Institute.
21. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the global assessment of functioning (GAF). Br J Psychiatry 1995, 166(5):654-659. 10.1192/bjp.166.5.654, 7620753.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:62.
23. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435. 10.1192/bjp.133.5.429, 728692.
24. Davison KM, Kaplan BJ. Vitamin and mineral intakes in adults with mood disorders: comparisons to nutrition standards and associations with sociodemographic and clinical variables. J Am Coll Nutr 2011, 30(6):547-558.
25. BC Ministry of Health Services British Columbia Nutrition Survey - Report on Energy and Nutrient Intakes 2004, Victoria: British Columbia: Ministry of Health Services, BC Ministry of Health Services.
26. Institute of Medicine Dietary Reference Intakes: Applications in Dietary Assessment 2000, Washington: National Academies Press, Institute of Medicine.
27. Sarkar U, Handley MA, Gupta R, Tang A, Murphy E, Seligman HK, Shojania KG, Schillinger D. What happens between visits? Adverse and potential adverse events among a low-income, urban, ambulatory population with diabetes. Qual Saf Health Care 2010, 19(3):223-228. 10.1136/qshc.2008.029116, 20378619.
28. Hendler SS. Rorvik DR, eds: PDR for Nutritional Supplements 2001, Montvale: Medical Economics Company, Inc..
29. Flodin N. Pharmacology of micronutrients 1988, New York: Alan R. Liss, Inc..
30. Debourdeau PM, Djezzar S, Estival JL, Zammit CM, Richard RC, Castot AC. Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. Ann Pharmacother 2001, 35(4):424-426.
31. Natural Standard Research Collaboration Natural Standard: The Authority on Integrative Medicine http://www.naturalstandard.com, Natural Standard Research Collaboration.
32. Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced mania. Biol Psychiatry 1999, 45:241-242. 10.1016/S0006-3223(98)00091-2, 9951574.
33. Johnson MD, Bebb RA, Sirrs SM. Uses of DHEA in aging and other disease states. Ageing Res Rev 2002, 1:29-41. 10.1016/S0047-6374(01)00369-4, 12039447.
34. Grahame R, Robinson BV. Devil's claw (Harpagohytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 1981, 40(6):632. 10.1136/ard.40.6.632, 1000848, 7332387.
35. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf 1997, 17(5):342-356. 10.2165/00002018-199717050-00006, 9391777.
36. Belaiche P. Etude clinique de 630 cas d'artrose traits par le nebulisat aqueux d'Harpagophytum procumbens (Radix). Phytotherapy 1982, 1:22-28.
37. Sood A, Sood R, Brinker FJ, Mann R, Loehrer LL, Wahner-Roedler DL. Potential for interactions between dietary supplements and prescription medications. Am J Med 2008, 121(3):207-211. 10.1016/j.amjmed.2007.11.014, 18328304.
38. Huntley AL, Thompson Coon J, Ernst E. The safety of herbal medicinal products derived from Echinacea species: a systematic review. Drug Saf 2005, 28(5):387-400. 10.2165/00002018-200528050-00003, 15853441.
39. Anonymous Immunallergische reaktionen nach Echinacea-estrakten (Echinacin, Exberitox N U.A.). Arnzei-telegramm 1991, 39. Anonymous.
40. Janes SE, Price CS, Thomas D. Essential oil poisoning: N-acetylcysteine for eugenol-induced hepatic failure and analysis of a national database. Eur J Pediatr 2005, 164(8):520-522. 10.1007/s00431-005-1692-1, 15895251.
41. Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med 1982, 6(4):375-379.
42. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988, 2(8604):189-192.
43. Awang DVC. Parthenocide: the demise of facile theory of feverfew activity. J Herbs Spices Med Plants 1998, 5(4):95-98.
44. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985, 291:569-573. 10.1136/bmj.291.6495.569, 1418227, 3929876.
45. Sriramarao P, Rao PV. Allergenic cross-reactivity between Parthenium and ragweed pollen allergens. Int Arch Allergy Immunol 1993, 100(1):79-85. 10.1159/000236391, 8428168.
46. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999, 56:407-412. 10.1001/archpsyc.56.5.407, 10232294.
47. Tarpila S, Kivinen A. Ground flaxseed is an effective hypolipidemic bulk laxative [published abstract]. Gastroenterology 1997, 112:A836.
48. Cunnane SC, Hamadeh MJ, Liede AC, Thompson LU, Wolever TM, Jenkins DJ. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 1995, 61(1):62-68.
49. Alonso L, Marcos ML, Blanco JG, Navarro JA, Juste S, del Mar GM, Perez R, Carretero PJ. Anaphylaxis caused by linseed (flaxseed) intake. J Allergy Clin Immunol 1996, 98(2):469-470. 10.1016/S0091-6749(96)70175-6, 8757228.
50. Lezaun A, Fraj J, Colas C, Duce F, Dominguez MA, Cuevas M, Eiras P. Anaphylaxis from linseed. Allergy 1998, 53(1):105-106. 10.1111/j.1398-9995.1998.tb03785.x, 9491240.
51. Morbidoni L, Arterburn J, Young V, Mullins D, Mulrow C, Lawrence V. Garlic: Its history and adverse effects. J Herb Pharmacother 2001, 1(1):63-83.
52. Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990, 26(5):880-882. 10.1227/00006123-199005000-00026, 2352608.
53. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008, 9:1063-1120. 10.2174/138920008786927785, 19075623.
54. Burkard G. The efficacy and safety of ginkgo biloba extract in dementia. Fortschr Med [Supp] 1991, 109(107):6-8.
55. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25(10):567-579. 10.1016/S0828-282X(09)70715-9, 2782500, 19812802.
56. Tomb RR, Fossereau J, Sell Y. Mini-epidemic of contact dermatitis from ginkgo tree fruit (Ginkgo biloba L.). Contact Dermatitis 1988, 19(4):281-283. 10.1111/j.1600-0536.1988.tb02928.x, 3219836.
57. Becker LE, Skipworth GB. Ginkgo- tree dermatitis, stomatitis, and proctitis. JAMA 1975, 231(11):1162-1163. 10.1001/jama.1975.03240230036017, 1172817.
58. Davydov L, Stirling AL. Stevens-Johnson syndrome with Ginkgo biloba. J Herb Pharmacother 2001, 1(3):65-69.
59. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Mar Ther 1998, 24:139-143.
60. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol 2000, 40(6):647-654. 10.1177/00912700022009297, 10868316.
61. Winther KA, Randløv C, Rein E, Mehlsen J. Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. CTR 1998, 59(12):881-888.
62. Yoshioka M, Ohnishi N, Sone N, Egami S, Takara K, Yokoyama T, Kuroda K. Studies on interactions between functional foods or dietary supplements and medicine III. Effects of ginkgo biloba leaf extract on the pharmacokinetics of nidedipine in rats. Biol Pharm Bull 2004, 27(12):2042-2045. 10.1248/bpb.27.2042, 15577230.
63. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. Studies on interactions between functional food or dietary supplements and medicine IV. Effects of ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004, 27(12):2006-2009. 10.1248/bpb.27.2006, 15577221.
64. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf 2002, 25(5):323-344. 10.2165/00002018-200225050-00003, 12020172.
65. Vuksan V, Sievenpiper JL, Koo VY, Francis T, Beljan-Zdravkovic U, Xu Z, Vidgen E. American ginseng Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Int Med 2000, 160(7):1009-1013.
66. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997, 54(6):692-693.
67. Cheng TO. Ginseng-warfarin interaction. ACC Curr J Rev 2000, 9(1):84.
68. Ding DZ, Shen TK, Cui YZ. Effects of red ginseng on the congestive heart failure and its mechanism. Chin J Integr Med 1995, 15(6):325-327.
69. Lee YJ, Jin YR, Lim WC, Park WK, Cho JY, Hang S, Lee SK. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res 2003, 26(1):58-63. 10.1007/BF03179933, 12568360.
70. Bae EA, Shin JE, Kim DH. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull 2005, 28(10):1903-1908. 10.1248/bpb.28.1903, 16204943.
71. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, Lee S. A ginsenoside-RH1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol 2003, 84(4):464-468.
72. Becker BN, Greene J, Evanson J, Chidsey G, Stone WJ. Ginseng-induced diuretic resistance. JAMA 1996, 276(8):606-607.
73. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987, 7(3):201-202. 10.1097/00004714-198706000-00030, 3597812.
74. Fugh-Berman A. Herb-drug interactions. Lancet 2000, 355(9198):134-138. 10.1016/S0140-6736(99)06457-0, 10675182.
75. Shader RI, Greenblatt DJ. Phenelzine and the dream machine-ramblings and reflections. J Clin Psychopharmacol 1985, 5(2):65. 10.1097/00004714-198504000-00001, 3988971.
76. Smith M, Lin KM, Zheng YP. PIII-89 an open trial of nifedipine-herb interations: nifedipine with St. John's wort, ginseng or ginkgo biloba. Clin Pharmacol Ther 2001, 69:86.
77. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006, 21:S25-S29. 10.1097/01.yic.0000195658.91524.61, 16436937.
78. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997, 65(5 Suppl):1687S-1698S.
79. Archer SL, Green D, Chamberlain M, Dyer AR, Liu K. Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol 1998, 18(7):1119-1123. 10.1161/01.ATV.18.7.1119, 9672072.
80. Weksler BB. Omega 3 fatty acids have multiple antithrombotic effects. World Rev Nutr Diet 1994, 76:47-50.
81. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greeland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980, 208(5):401-406.
82. Stacpoole PW, Alig J, Ammon L, Crockett SE. Dose-response effects of dietary marine oil on carbohydrate and lipid metabolism in normal subjects and patients with hypertriglyceridemia. Metabolism 1989, 38(10):946-956. 10.1016/0026-0495(89)90004-8, 2677610.
83. Vanschoonbeek K, Feijge MA, Paquay M, Rosing J, Saris W, Kluft C, Giesen PL, de Maat MP, Heemskerk JW. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004, 24(9):1734-1740. 10.1161/01.ATV.0000137119.28893.0b, 15217806.
84. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998, 21(4):494-500. 10.2337/diacare.21.4.494, 9571330.
85. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000, 23(9):1407-1415. 10.2337/diacare.23.9.1407, 10977042.
86. Goodnight SH, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981, 58(5):880-885.
87. von Houwelingen R, Nordøy A, van der Beek E, Houtsmuller U, de Metz M, Hornstra G. Effect of a moderate fish intake on blood pressure, bleeding time, haematology, and clinical chemistry in healthy males. Am J Clin Nutr 1987, 46(3):424-436.
88. Lorenz R, Spengler U, Fischer S, Duhm J, Weber PC. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 1983, 67(3):504-511. 10.1161/01.CIR.67.3.504, 6821892.
89. Ahmed AA, Holub BJ. Alteration and recovery of bleeding times, platelet aggregation and fatty acid composition of individual phospholipids in platelets of human subjects receiving a supplement of cod-liver oil. Lipids 1984, 19(8):617-624. 10.1007/BF02534720, 6090856.
90. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother 2004, 38(1):50-52.
91. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on " reaction time, alertness, and concentration" in volunteers. Pharmacopsychiatry 1999, 32:235-241. 10.1055/s-2007-991100, 10599933.
92. Gerhard U, Linnenbrink N, Georghiadou C, Hobi V. Vigilanzmindernde Effekte zweier pfazlicher Schlafmittel (Effects of two plant-based sleep remedies on vigilance). Schweiz Rundsch Med Prax 1996, 85:473-481.
93. Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988, 21:447-448. 10.1055/s-2007-1017047, 3244789.
94. Boeters VU. On treatment of control disorders of the autonomic nervous system with valepotraten (Valmane). Munch Med Wochenschr 1969, 37:1873-1876.
95. Leathwood PD, Chaufard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985, 2:144-148.
96. Kamm-Kohl AV, Jansen W, Brockmann P. Moderne baldrian-therpie gegen nervose Storungen in Senium. Medwelt 1984, 35:1450-1454.
97. Seifert T. Therapeutic effects of valerian in nervous disorders. Therapeutikon 1988, 2:94-98.
98. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delerium associated with valerian root withdrawal. JAMA 1998, 280:1566-1567. 10.1001/jama.280.18.1566, 9820254.
99. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicity of herbal remedies. BMJ 1989, 299(6708):1156-1157. 10.1136/bmj.299.6708.1156, 1838039, 2513032.
100. Plushner SL. Valerian: Valeriana. Officinalis. Am J Health Syst Pharm 2000, 57(4):328-333. 335.
101. Muller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety-results of an open, practice-oriented study with St. John's wort WS 5572 and valerian extract in high doses. Phytomedicine 2003, 10(Suppl 4):25-30.
102. Katzman MA, Jacobs L, Marcus M, Vermani M, Logan AC. Weight gain and psychiatric treatment: is there a role for green tea and conjugated linoleic acid?. Lipids Health Dis 2007, 6:14. 10.1186/1476-511X-6-14, 1876457, 17477874.
103. Lipowski ZJ. Somatization: the concept and its clinical applications. Am J Psychiatry 1988, 145:1358-1368.
104. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998, 279:1548-1553. 10.1001/jama.279.19.1548, 9605899.
105. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and mineral supplement use in the United States. Arch Fam Med 2000, 9:258-262. 10.1001/archfami.9.3.258, 10728113.
106. Davison KM, Kaplan BJ. Nutrient intakes are correlated with overall psychiatric functioning in adults with mood disorders. Can J Psychiatry 2012, 57(2):85-92.